According to a report in The Wall Street Journal, Pfizer is showing interest in buying Seagen. if this deal happens then it can be worth 30 billion USD or more.   Image Source - Bloomberg

Seagen Inc. is a biotechnology company working on antibody-based therapies for the treatment of cancer. The valuation of this company is around $30 billion USD.   Image Source - Twitter

Last year news came that Seagen could be acquired by Merck and if this deal had happened, it could have been worth USD 40 billion or more. But the deal could not happen.

Last year Pfizer has also acquired two big companies. Global Blood Therapeutics Inc. - USD 5 billion and Biohaven Pharmaceutical Holdings Co. - USD 10 billion.   Image Source - youtube

Seagen, a pioneer of a type of treatment for cancer called antibody-based drug conjugates. Image Source - reuters

This functions as a missile that is guided in that targets tumors with toxic substances. Image Source - reuters

The possibilities of breast cancer may be especially attractive to Pfizer with its most popular drug, called Ibrance which treats the disease.

The size of the global cancer therapeutics market in 2021 was approximately USD 166.5 billion and by 2029 this market will be USD 335.06 billion. CAGR 9.1%. Image Source - mayo clinic

Seeing this kind of growth, different drug making companies will get attracted towards it and will definitely try to add this number to their balance sheet. Image Source - The Economic Times

Now it remains to be seen whether this deal gets finalized or not. If this happens, then Pfizer can be successful in making a huge place this market. Image Source - inc.com